Sudhakar has 23 years of oncology drug discovery and project leadership experience, with a proven track record of building and leading high-performing, cross-functional teams and advancing multiple new molecular entities from early discovery through clinical proof-of-concept. He previously served as Senior Director, Project Team Leadership in Oncology R&D at Pfizer, where he led multidisciplinary teams and helped shape early clinical and development strategies across tumor-targeting and immuno-oncology programs.
Prior to Pfizer, Sudhakar held research and group leadership roles at Eli Lilly and Company (including within tumor microenvironment, cancer angiogenesis, and immuno-oncology/myeloid biology). At Lilly, he was a significant contributor to the development and regulatory approvals of ramucirumab (Cyramza) and led translational efforts supporting multiple clinical starts, while also advancing best- and first-in-class biologics and small-moleculetherapies into early clinical studies. Sudhakar earned a PhD in Biochemistry and Biophysics and an MS in Chemistry from Texas A&M University, and a DVM from Acharya N.G. Ranga Agricultural University.
A committed inclusive leader and mentor, Sudhakar has been recognized for his contributions to diversity and inclusion, including the Lilly Research Labs (LRL) President’s Diversity and Inclusion Award and a Global Diversity and Inclusion Marketplace Award. He is also a prolific scientific contributor with 50+ publications in high-impact journals and 50+ poster presentations, and is a co-inventor on multiple patents.
